Ferriprox (deferiprone) is a chelating agent with an affinity for ferric ion (iron III). Deferiprone binds with ferric ions to form neutral complexes that are stable over a wide range of pH values.
Ferriprox is specifically indicated for patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Ferriprox is supplied as a tablet for oral administration. The recommended initial dose is 25 mg/kg, orally, three times per day for a total of 75 mg/kg/day. The maximum dose is 33 mg/kg, three times per day for a total of 99 mg/kg/day. A new formulation of Ferriprox was approved in May of 2020. The new formulation of twice-a-day Ferriprox 1000 mg oral tablets allows for twice-daily dosing.
The FDA approval of Ferriprox was based on 12 clinical studies in 236 subjects who did not respond to prior iron chelation therapy. Ferriprox therapy (35-99 mg/kg/day) was considered successful in individuals who experienced a greater than or equal to 20% decline in serum ferritin within one year of starting therapy. Of the 236 enrolled subjects, 50% reached the endpoint of at least a 20% reduction in serum ferritin.
Adverse events associated with the use of Ferriprox may include, but are not limited to, the following:
Ferriprox is a chelating agent with an affinity for ferric ion (iron III). Deferiprone binds with ferric ions to form neutral complexes that are stable over a wide range of pH values.
Jamuar SS, Lai AH, Tan AM, Chan MY, Tan ES, Ng IS Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia. Journal of Paediatrics and Child Health. 2011 Sep 9. doi: 10.1111/j.1440-1754.2011.02031
Akrawinthawong K, Chaowalit N, Chatuparisuth T, Siritanaratkul N Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology 2011 Mar;16(2):113-22
For additional information regarding Ferriprox or transfusional iron overload due to thalassemia, please visit the Ferriprox web page.